Urology News and Research

Latest Urology News and Research

U-M researchers develop first-ever 3D model to help study treatment for pelvic organ prolapse

It's a mysterious condition often linked to childbirth that causes distress and discomfort and requires surgery for more than 200,000 women a year - but there's no good way to study it. Now, researchers at the University of Michigan have developed the first-ever 3D complete computer model to help study treatment for pelvic organ prolapse, a weakening of muscles and ligaments that causes organs like the bladder to drop from their normal place. For many women, the condition causes urinary problems, painful intercourse and uncomfortable pressure.

9 Jul 2015

Study examines recent trends in community-based practices to improve management of localized prostate cancer

After years of overtreatment for patients with low-risk prostate cancer, rates of active surveillance/ watchful waiting increased sharply in 2010 through 2013, and high-risk disease was more often treated appropriately with potentially curative local treatment rather than androgen deprivation alone, according to a study in the July 7 issue of JAMA.

8 Jul 2015

Spotting the symptoms of advanced prostate cancer: an interview with Brian Tomlinson

The main symptoms of advanced prostate cancer can include (but are not limited to) difficulty walking or climbing steps, unexplained pain, troubled sleep and taking pain relievers daily.

From CancerCare 7 Jul 2015

Aytu BioScience now trading under new symbol following its corporate name change

Aytu BioScience, Inc., a specialty healthcare company focused on developing treatments for urological and related conditions, announced today that the company is now trading under the new symbol "AYTU," following its corporate name change, which became effective June 8, 2015.

7 Jul 2015

Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Allergan plc and Merck, known as MSD outside the United States and Canada, today announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).

7 Jul 2015

Study focuses on health risks from exposure to air pollution near roads and freeways

Policymakers and developers planning high-density housing near public transit with the goal of reducing automobile use and greenhouse gas emissions that contribute to global warming need a clearer understanding of the health risks from air pollution that may be created if that housing is also built near busy roads and freeways, according to new research by Keck School of Medicine of the University of Southern California scientists.

7 Jul 2015

Expectant management remains underused for men with low-risk prostate cancer

Monitoring men with very low- and low-risk prostate cancers using watchful waiting or active surveillance, called expectant management, is a useful approach for a large number of men with localized tumors and could spare them the debilitating side effects of aggressive treatments that are too often unnecessarily used in this patient population, a UCLA review of common practices in prostate cancer has found.

7 Jul 2015

Allergan enters into agreement to acquire Oculeve

Allergan plc, a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused on developing novel treatments for dry eye disease, today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction.

6 Jul 2015

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

In the first study of its kind, Penn researchers have shown how an anti-diabetic drug can have variable effects depending on small natural differences in DNA sequence between individuals. Mitchell Lazar, MD, PhD, Raymond Soccio, MD, PhD, and colleagues at the Perelman School of Medicine at the University of Pennsylvania, aim to apply this knowledge to develop personalized approaches to treating diabetes and other metabolic disorders.

3 Jul 2015

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.

2 Jul 2015

New review may help women with stress urinary incontinence make more informed choices about treatment

A new Cochrane systematic review published today of surgery for stress urinary incontinence makes an important contribution to an ongoing debate and will help women to make more informed choices about treatment.

1 Jul 2015

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

America's oldest cancer center and one of the world's newest oncology centers are partnering to improve access to cancer prevention, screening and care for the people of Nigeria. Roswell Park Cancer Institute and Lakeshore Cancer Center have announced an affiliation that will see Roswell Park faculty providing clinical consultations to assist LCC oncologists, who will also have access to both training at RPCI and continuing professional education seminars they can participate in remotely.

1 Jul 2015

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories.

30 Jun 2015

Telesta submits Biologics License Application for MCNA to FDA

Telesta Therapeutics Inc. announced today that it has submitted electronically, through its U.S. agent, a Biologics License Application (BLA) to the United States Food and Drug Administration for MCNA. MCNA is Telesta's novel biologic immunotherapeutic for the treatment of high-risk non-muscle invasive bladder cancer patients who have failed first-line BCG therapy.

30 Jun 2015

E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

Investigators from Dartmouth's Norris Cotton Cancer Center harnessed genomic data to discover that the previously identified E2F4 signature in breast cancer can be utilized to predict prognosis and response to therapy in bladder cancer.

25 Jun 2015

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

US-Australian drug discovery company, Novogen Limited announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the clinic.

24 Jun 2015

Johns Hopkins researchers identify multiple genetic changes that may increase risk of pancreatic cancer

In a genome-wide association study believed to be the largest of its kind, Johns Hopkins researchers have uncovered four regions in the human genome where changes may increase the risk of pancreatic cancer.

24 Jun 2015

Drugs used against impotence does not increase risk of malignant melanoma

Using drugs for impotence does not increase the risk of malignant melanoma, researchers from Umeå University in Sweden conclude in a publication in JAMA, a top US medical journal. These results contradict previous research indicating such an association.

23 Jun 2015

Bariatric surgery can significantly reduce urinary incontinence

For severely obese people, bariatric surgery may have a benefit besides dramatic weight loss: it can also substantially reduce urinary incontinence.

23 Jun 2015

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

The Minimally Invasive Urology Institute at The Miriam Hospital is offering UroLift as one of the newest surgical treatments available for men with benign prostatic hyperplasia (BPH), an enlarged prostate condition.

23 Jun 2015

Urology News and Research

Latest Urology News and Research

U-M researchers develop first-ever 3D model to help study treatment for pelvic organ prolapse

Study examines recent trends in community-based practices to improve management of localized prostate cancer

Spotting the symptoms of advanced prostate cancer: an interview with Brian Tomlinson

Aytu BioScience now trading under new symbol following its corporate name change

Allergan agrees to acquire exclusive worldwide rights to Merck's CGRP migraine development program

Study focuses on health risks from exposure to air pollution near roads and freeways

Expectant management remains underused for men with low-risk prostate cancer

Allergan enters into agreement to acquire Oculeve

Penn study suggests future precision medicine approach to treating diabetes, other metabolic disorders

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

New review may help women with stress urinary incontinence make more informed choices about treatment

Roswell Park, Lakeshore Cancer Center partner to improve access to cancer care for Nigerians

BioLight receives CE Mark approval for CellDetect bladder cancer test

Telesta submits Biologics License Application for MCNA to FDA

E2F4 biomarker can help predict prognosis and response to BCG therapy in bladder cancer

Novogen’s chemotherapy drug Anisina proves as effective anti-cancer agent in animals

Johns Hopkins researchers identify multiple genetic changes that may increase risk of pancreatic cancer

Drugs used against impotence does not increase risk of malignant melanoma

Bariatric surgery can significantly reduce urinary incontinence

The Miriam Hospital offers new surgical treatment for benign prostatic hyperplasia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Urology News and Research

Latest Urology News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in